文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

印度非小细胞肺癌患者中具有临床相关性的基因组改变图谱。

Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.

机构信息

Department of Research, Karkinos Foundation, Mumbai, Maharashtra, India; Division of Cancer Biology, Karkinos Healthcare Pvt Ltd, Navi Mumbai, Maharashtra, India.

Division of Cancer Biology, Karkinos Healthcare Pvt Ltd, Navi Mumbai, Maharashtra, India.

出版信息

Clin Lung Cancer. 2024 Dec;25(8):e420-e430.e20. doi: 10.1016/j.cllc.2024.07.011. Epub 2024 Jul 22.


DOI:10.1016/j.cllc.2024.07.011
PMID:39129089
Abstract

BACKGROUND: The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights for implementation of precision therapies. METHODS: We analyzed the genomic profiles of 325 lung adenocarcinoma and 81 lung squamous carcinoma samples from Indian patients using targeted sequencing of 50 cancer related genes. Correlations between genomic alterations and clinical characteristics were computed using statistical analyses. Additionally, we identified distinct features of Indian NSCLC genomes by comparison across different ethnicities. RESULTS: Our genomic analysis revealed several noticeable features of Indian NSCLC patients. Alterations in EGFR (45.8%), TP53 (27.4%), ALK (11.4%) and KRAS (10.2%) were predominant in adenocarcinoma, with 68% eligible for targeted therapies. Squamous carcinoma exhibited prevalent alterations in TP53 (40.7%), PIK3CA (17.3%), and CDKN2A (8.6%). We observed higher frequency of EGFR alterations (18.5%) in lung squamous carcinoma patients, significantly distinct from other ethnicities reported till date. Beyond established correlations, we observed 60% of PD-L1 negative squamous patients harbored TP53 alterations, suggesting intriguing therapeutic implications. CONCLUSIONS: Our data revealed unique genomic variations of adenocarcinoma and squamous carcinoma patients, with significant indications for precision medicine and clinical practice of lung cancers. The study emphasizes the importance of clinical utility of NGS for routine diagnostics.

摘要

背景:印度非小细胞肺癌(NSCLC)患者的基因组图谱仍未得到充分探索。我们揭示了印度 NSCLC 患者独特的基因组改变,从而为实施精准治疗提供了重要的分子见解。

方法:我们使用 50 个与癌症相关基因的靶向测序,分析了 325 例肺腺癌和 81 例肺鳞癌样本的基因组图谱。使用统计分析计算了基因组改变与临床特征之间的相关性。此外,我们通过与不同种族的比较,确定了印度 NSCLC 基因组的独特特征。

结果:我们的基因组分析揭示了印度 NSCLC 患者的几个显著特征。腺癌中 EGFR(45.8%)、TP53(27.4%)、ALK(11.4%)和 KRAS(10.2%)的改变最为常见,其中 68%有资格接受靶向治疗。鳞癌中 TP53(40.7%)、PIK3CA(17.3%)和 CDKN2A(8.6%)的改变更为常见。我们观察到肺鳞癌患者中 EGFR 改变的频率更高(18.5%),与迄今为止报道的其他种族明显不同。除了已建立的相关性外,我们还观察到 60%的 PD-L1 阴性鳞癌患者存在 TP53 改变,这提示了有趣的治疗意义。

结论:我们的数据揭示了腺癌和鳞癌患者独特的基因组变异,为精准医学和肺癌的临床实践提供了重要依据。该研究强调了 NGS 在常规诊断中的临床应用的重要性。

相似文献

[1]
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.

Clin Lung Cancer. 2024-12

[2]
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.

JCO Glob Oncol. 2025-5

[3]
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

Lung Cancer. 2020-1

[4]
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.

Oncologist. 2019-3-22

[5]
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.

Thorac Cancer. 2020-1

[6]
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

Clin Lung Cancer. 2020-5

[7]
The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.

J Thorac Oncol. 2019-4-9

[8]
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.

J Cancer Res Ther. 2021

[9]
Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.

Technol Cancer Res Treat. 2024

[10]
The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

J Thorac Oncol. 2012-12

引用本文的文献

[1]
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.

Front Med (Lausanne). 2025-7-30

[2]
Utility and real-world clinical outcomes of next-generation sequencing in advanced non-small-cell lung cancer in the South Indian population.

Oncologist. 2025-7-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索